ACVR2A and pulmonary arterial hypertension: In this report, we compared the effects of ActRIIA-Fc with those of the phosphodiesterase type 5 inhibitor sildenafil in PAH models and found far greater anti-inflammatory efficacy for ActRIIA-Fc.